drug
allopurinol
Marketedupdated 3mo agoby Casper Pharma LLC
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 6indications
investigational
Duchenne Muscular Dystrophy
all catalysts(0)
nothing on the calendar yet
Trials studying allopurinol
- phase2Phase II Study to Evaluate Efficacy and Safety of D-0120 in Combination With Allopurinol in Subjects With Gout
- phase3A Study of Dotinurad Versus Allopurinol in Participants With Gout
- phase3A Study of Dotinurad Versus Allopurinol in Tophaceous Gout
- phase1Drug-Drug Interaction Study of ABP-671 in Gout Patients
- phase2Time-limited Triplet Combination of Pirtobrutinib, Venetoclax, and Obinutuzumab for Patients With Treatment-naïve Chronic Lymphocytic Leukemia (CLL) or Richter Transformation (RT)
- phase3Phase 2b/3 Study to Assess ABP-671 a Novel URAT1 Inhibitor in Participants With Gout
- phase3Tigulixostat, Phase 3 Study, Allopurinol Controlled in Gout Patients
- phase3Extension Study of ABP-671 in Participants With Gout
Patent cliff
source: FDA Orange Bookfirst barrier falls
Nov 26, 2028
~2.3 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (16)
- Feb 29, 2032compositionUS 8546436
- Feb 29, 2032compositionUS 8546436
- Dec 28, 2031method-of-use (U-2104)US 9956205
- Dec 28, 2031method-of-use (U-2104)US 9956205
- Aug 1, 2031method-of-use (U-2104)US 92161795.0y
- Aug 1, 2031method-of-use (U-2104)US 92161795.0y
- Dec 22, 2029formulationUS 83577133.3y
- Dec 22, 2029formulationUS 83577133.3y
- Aug 17, 2029method-of-use (U-2104)US 80844833.0y
- Aug 17, 2029method-of-use (U-2104)US 80844833.0y
- Apr 29, 2029method-of-use (U-2104)US 85464372.7y
- Apr 29, 2029method-of-use (U-2104)US 85464372.7y
- Nov 26, 2028method-of-use (U-2104)US 101830122.3y
- Nov 26, 2028method-of-use (U-2104)US 101830122.3y
- Nov 26, 2028method-of-use (U-2104)US 82833692.3y
- Nov 26, 2028method-of-use (U-2104)US 82833692.3y
News(2)
- Crystalys nets $130M more to push gout drug through late-stage testsThe startup has a broad global development program underway — and the support of more than 20 investment firms — for a treatment that’s approved in many Asian countries but isn’t yet available in t…biopharma_dive · 26d ago
- Crystalys mines $130M series B to push gout drug through phase 3Crystalys Therapeutics has raised $130 million in series B financing to advance the development of its gout drug dotinurad and prepare for a potential commercial launch.fiercebiotech · 27d ago
Data sources
last refreshed 16m ago
Found something off?
comments(0)
5-min edit window · permanent after that